Revenue - Revenue from Licensing Arrangements (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	$ 7.5
Mylan
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	205.0
Upfront payment receivable	18.5
Mylan | Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	160.0
Mylan | Revefenacin Monotherapy (TD-4208) | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	150.0
Mylan | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	9.0
Mylan | YUPELRI Monotherapy | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	37.5
Mylan | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	45.0
Mylan | Future potential combination products | Development and Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	$ 54.0